The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

A Food and Drug Administration project to promote diversity in clinical studies of cancer treatments was removed from the ...

A major research breakthrough on Parkinson's disease revealed that an already FDA-approved cancer drug could help stem the ...

Roche Holding said the U.S. Food and Drug Administration approved a test to identify patients with a specific type of breast cancer. The Swiss pharmaceutical company said the FDA backed a label ...

T-DXd, an antibody-drug conjugate now approved for multiple tumor types, gained approval in 2022 for unresectable or metastatic HER2-low breast cancer -- defined by an FDA-approved test as IHC 1 ...

Groundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...

AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved trastuzumab deruxtecan for a new breast cancer indication. The approval applies to patients ...

has received approval from the US Food and Drug Administration (FDA) for an expanded indication of breast cancer patients with very low levels of HER2 protein. The drug is now cleared for use in ...

Trastuzumab deruxtecan is approved for HR ... ultralow metastatic breast cancer following endocrine therapy.” Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate (ADC) developed ...